1 September 2021 in Computers in Biology and Medicine
6 February 2026 in Computerized Medical Imaging and Graphics
Machine learning methods based on imaging and other clinical data have shown great potential for improving the early and accurate diagnosis of Alzheimer's disease (AD). However, for most deep learning models, especially those including high-dimensional imaging data, the decision-making process remains largely opaque which limits clinical applicability. Explainable Boosting Machines (EBMs) are inherently interpretable machine learning models, but are typically applied to low-dimensional data. In this study, we propose an interpretable machine learning framework that integrates data-driven feature extraction based on Convolutional Neural Networks (CNNs) with the intrinsic transparency of EBMs for AD diagnosis and prediction. The framework enables interpretation at both the group-level and individual-level by identifying imaging biomarkers contributing to predictions. We validated the framework on the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, achieving an area-under-the-curve (AUC) of 0.969 for AD vs. control classification and 0.750 for MCI conversion prediction. External validation was performed on an independent cohort, yielding AUCs of 0.871 for AD vs. subjective cognitive decline (SCD) classification and 0.666 for MCI conversion prediction. The proposed framework achieves performance comparable to state-of-the-art black-box models while offering transparent decision-making, a critical requirement for clinical translation. Our code is available at: https://gitlab.com/radiology/neuro/interpretable_ad_classification.
1 January 2021 in SSRN Electronic Journal
The accurate diagnosis of Alzheimer's disease (AD) and its early stage is essential for early dementia detection and treatment planning. For 2D Convolutional neural networks (CNNs), the networks pre-trained on ImageNet always outperformed the models trained from scratch. 3D CNN is easily to lead to an overfitting problem due to the lack of 3D neuroimage datasets. To alleviate the overfitting caused by small to medium-sized datasets, a three-round learning strategy based on 3D Deep Convolutional Generative Adversarial Networks (DCGAN) is used for staging the spectrum of AD. In the first round, the common features of sMRI were trained in the context of 3D DCGAN by unsupervised learning. In the second round, the pre-trained discriminator (D) of the DCGAN with residual architecture was transferred and fine-tuned for the classification task between AD and cognitive normal (CN). In the last round of the transfer learning approach, the weights learned in the AD versus CN classification task were transferred to MCI diagnosis. The proposed model attained accuracies of 92.8%, 78.1%, and 76.4% in the classification of AD versus CN, AD versus MCI, and MCI versus CN, respectively. The experimental results demonstrate that our proposed model has a good classification performance on staging the AD spectrum with small to medium-sized datasets, compared with other state-of-the-art studies.